Key result
Administration of exogenous phosphocreatine in a patient with severe chemotherapy-induced cardiomyopathy improved left ventricular ejection fraction from 13% to 42% at follow-up.
Why the study?
Does exogenous phosphocreatine improve LVEF and symptoms in a patient with chemotherapy-induced cardiomyopathy?
Case Report (n=1)
No
Does exogenous phosphocreatine improve LVEF and symptoms in a patient with chemotherapy-induced cardiomyopathy?
Exogenous phosphocreatine may be a beneficial adjunctive metabolic therapy for improving cardiac function in severe chemotherapy-induced cardiomyopathy refractory to standard heart failure treatments.
May support adjunctive use in refractory chemotherapy-induced cardiomyopathy; leaves open confirmation in prospective trials.
The 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) regimen is widely used in the management of breast cancer. The common cardiotoxic effects of doxorubicin include congestive heart failure and left ventricular dysfunction, and those of cyclophosphamide include pericarditis, myocarditis, and congestive heart failure. It has been postulated that cardiotoxicity of 5-fluorouracil presents as coronary artery diseases (eg, angina). Cardiomyopathy is a common outcome following treatment with the FAC regimen. We report on a 52-year-old woman with cardiomyopathy following chemotherapy and radiation therapy. The patient did not respond well to b-blockers and angiotensin-converting enzyme inhibitors. After the addition of exogenous phosphocreatine, the patient's cardiac condition improved significantly.
No takes yet. Share an insight, caveat, or question.
Parve et al. (2017) conducted a case report in Chemotherapy-induced cardiomyopathy (n=1). Exogenous phosphocreatine was evaluated on Left ventricular ejection fraction (LVEF). Administration of exogenous phosphocreatine in a patient with severe chemotherapy-induced cardiomyopathy improved left ventricular ejection fraction from 13% to 42% at follow-up.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: